Factors Associated with Indacaterol Response in Tuberculosis-Destroyed Lung with Airflow Limitation

Tuberculosis and Respiratory Diseases

article

Tae Hoon Kim¹  Chin Kook Rhee²  Yeon-Mok Oh¹ 

[1] Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine;Division of Pulmonary, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea

关键词: Tuberculosis;    Pulmonary Disease;    Chronic Obstructive;    Indacaterol;    Smoking;   

DOI  :  10.4046/trd.2018.0050

学科分类：医学（综合）

来源: The Korean Academy of Tuberculosis and Respiratory Diseases

【 摘 要 】

Background Pulmonary tuberculosis can result in anatomical sequelae, and cause airflow limitation. However, there are no treatment guidelines for patients with a tuberculosis-destroyed lung. Recently, indacaterol effectiveness in chronic obstructive pulmonary disease (COPD) patients with Tuberculosis history (INFINITY) study revealed indacaterol provided bronchodilation and symptom improvement in COPD patients with a tuberculosis-destroyed lung. Methods We conducted a post-hoc subgroup analysis of the randomized controlled trial, the INFINITY study, to determine factors associated with indacaterol response in a tuberculosis-destroyed lung with airflow limitation. Data from 68 patients treated with inhaled indacaterol, were extracted and analyzed. Factors associated with the response of forced expiratory volume in one second (FEV 1 ) to indacaterol treatment, were determined using linear regression analysis. Results Of 62 patients included, 68% were male, and 52% had history of cigarette smoking. Patients revealed mean FEV 1 of 50.5% of predicted value with mean improvement of 81.3 mL in FEV 1 after indacaterol treatment for 8 weeks. Linear regression analysis revealed factors associated with response of FEV 1 to indacaterol included a short duration of smoking history, and high short-acting bronchodilator response. When patients with history of smoking were excluded, factors associated with response of FEV 1 to indacaterol included high short-acting bronchodilator response, and poor healthrelated quality of life score as measured by St. George's Respiratory Questionnaire for COPD. Conclusion In a tuberculosis-destroyed lung with airflow limitation, short-acting bronchodilator response and smoking history can play a critical role in predicting outcomes of indacaterol treatment.

【 授权许可】

CC BY-NC